-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $82

Benzinga·05/27/2026 13:51:30
Listen to the news
JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and raises the price target from $80 to $82.